Physician profile
Mini P Pathrose
NPI 1538168844
$12,768.70
in general payments reported to CMS, 2019-2025
50 companies · $2,627 in 2025
The $2,627 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $841 · 2021: $1,359 · 2022: $1,619 · 2023: $2,072 · 2024: $2,478 · 2025: $2,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,170 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,170.47 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,702.63 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,648.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,189.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $965.57 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $953.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $765.35 | 2019-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Glaxosmithkline, LLC. | $714.33 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $610.17 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $555.82 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $503.84 | 2021-2025 | |
| Amgen INC. | $451.39 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $314.76 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Novartis Pharmaceuticals Corporation | $248.63 | 2019-2025 | |
| Exact Sciences Corporation | $215.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $196.55 | 2019-2023 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mini Pathrose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.